Literature DB >> 20033296

Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes-possibility for newborn screening.

Zoltan Lukacs1, Paulina Nieves Cobos, Eugen Mengel, Ralf Hartung, Michael Beck, Marcus Deschauer, Angelika Keil, René Santer.   

Abstract

BACKGROUND: Pompe disease is a rare, autosomal-recessive disorder which results from a defect in the lysosomal enzyme acid alpha-glucosidase (GAA). The onset of this disease is highly variable, with infantile types being the most severe. Traditionally, lymphocytes, fibroblasts or muscle biopsies were necessary for enzyme activity measurement, because these materials do not express maltase-glucoamylase (MGA) that interferes with the assay. Recently, acarbose was found to inhibit MGA activity selectively, so that dried blood became accessible for GAA assessment. AIM: To evaluate the diagnostic efficacy of GAA measurement in dried blood specimens (DBSs) in comparison with lymphocytes. If DBSs provided reliable results, the diagnosis of Pompe disease could be facilitated, and high-throughput screening would become possible. METHODS AND
RESULTS: GAA activity was measured in DBSs of known patients at pH 3.8 (with and without acarbose) and at pH 7.0. Additionally, lymphocytes were obtained from the same patients, and the enzyme activity was determined at pH 4 to pH 7. In total, seven infantile patients and 29 patients with late-onset variants were investigated. All patients were reliably identified by both methods. Furthermore, a simplified protocol was established for neonatal screening.
CONCLUSION: The fluorometric technique for the assessment of GAA activity in DBS provides a reliable diagnosis for all variants of Pompe disease. The assay protocol could be simplified for neonatal screening, without increasing the false positive rate significantly or burdening the laboratory with time-consuming procedures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20033296     DOI: 10.1007/s10545-009-9003-z

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper.

Authors:  Néstor A Chamoles; Gabriela Niizawa; Mariana Blanco; Daniela Gaggioli; Carina Casentini
Journal:  Clin Chim Acta       Date:  2004-09       Impact factor: 3.786

2.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.

Authors:  Priya S Kishnani; Wuh-Liang Hwu; Hanna Mandel; Marc Nicolino; Florence Yong; Deyanira Corzo
Journal:  J Pediatr       Date:  2006-05       Impact factor: 4.406

3.  Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.

Authors:  B Winchester; D Bali; O A Bodamer; C Caillaud; E Christensen; A Cooper; E Cupler; M Deschauer; K Fumić; M Jackson; P Kishnani; L Lacerda; J Ledvinová; A Lugowska; Z Lukacs; I Maire; H Mandel; E Mengel; W Müller-Felber; M Piraud; A Reuser; T Rupar; I Sinigerska; M Szlago; F Verheijen; O P van Diggelen; B Wuyts; E Zakharova; J Keutzer
Journal:  Mol Genet Metab       Date:  2007-12-19       Impact factor: 4.797

4.  A new diagnostic assay for glycogen storage disease type II in mixed leukocytes.

Authors:  Toshika Okumiya; Joke L M Keulemans; Marian A Kroos; Nadine M E Van der Beek; Marijke A Boer; Hiroaki Takeuchi; Otto P Van Diggelen; Arnold J J Reuser
Journal:  Mol Genet Metab       Date:  2005-12-15       Impact factor: 4.797

Review 5.  Management and treatment of glycogenosis type II.

Authors:  B Bembi; E Cerini; C Danesino; M A Donati; S Gasperini; L Morandi; O Musumeci; G Parenti; S Ravaglia; F Seidita; A Toscano; A Vianello
Journal:  Neurology       Date:  2008-12-02       Impact factor: 9.910

Review 6.  Pompe's disease.

Authors:  Ans T van der Ploeg; Arnold J J Reuser
Journal:  Lancet       Date:  2008-10-11       Impact factor: 79.321

7.  Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.

Authors:  Yin-Hsiu Chien; Shu-Chuan Chiang; Xiaokui Kate Zhang; Joan Keutzer; Ni-Chung Lee; Ai-Chu Huang; Chun-An Chen; Mei-Hwan Wu; Pei-Hsin Huang; Fu-Jen Tsai; Yuan-Tsong Chen; Wuh-Liang Hwu
Journal:  Pediatrics       Date:  2008-06-02       Impact factor: 7.124

8.  High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population.

Authors:  Shingo Kumamoto; Tatsuya Katafuchi; Kimitoshi Nakamura; Fumio Endo; Eri Oda; Torayuki Okuyama; Marian A Kroos; Arnold J J Reuser; Toshika Okumiya
Journal:  Mol Genet Metab       Date:  2009-03-18       Impact factor: 4.797

9.  Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease.

Authors:  Haoyue Zhang; Helmut Kallwass; Sarah P Young; Cortney Carr; Jian Dai; Priya S Kishnani; David S Millington; Joan Keutzer; Yuan-Tsong Chen; Deeksha Bali
Journal:  Genet Med       Date:  2006-05       Impact factor: 8.822

10.  Pompe disease diagnosis and management guideline.

Authors:  Priya S Kishnani; Robert D Steiner; Deeksha Bali; Kenneth Berger; Barry J Byrne; Laura E Case; Laura Case; John F Crowley; Steven Downs; R Rodney Howell; Richard M Kravitz; Joanne Mackey; Deborah Marsden; Anna Maria Martins; David S Millington; Marc Nicolino; Gwen O'Grady; Marc C Patterson; David M Rapoport; Alfred Slonim; Carolyn T Spencer; Cynthia J Tifft; Michael S Watson
Journal:  Genet Med       Date:  2006-05       Impact factor: 8.822

View more
  9 in total

1.  Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.

Authors:  Monica Del Rizzo; Marina Fanin; Alessia Cerutti; Chiara Cazzorla; Ornella Milanesi; Anna Chiara Nascimbeni; Corrado Angelini; Laura Giordano; Andrea Bordugo; Alberto B Burlina
Journal:  J Inherit Metab Dis       Date:  2010-09-10       Impact factor: 4.982

Review 2.  Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.

Authors:  Gauthier Remiche; Dario Ronchi; Francesca Magri; Costanza Lamperti; Andreina Bordoni; Maurizio Moggio; Nereo Bresolin; Giacomo P Comi
Journal:  J Neurol       Date:  2013-10-25       Impact factor: 4.849

3.  Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness.

Authors:  Zoltan Lukacs; Paulina Nieves Cobos; Stephan Wenninger; Tracey A Willis; Michela Guglieri; Marc Roberts; Rosaline Quinlivan; David Hilton-Jones; Teresinha Evangelista; Stephan Zierz; Beate Schlotter-Weigel; Maggie C Walter; Peter Reilich; Thomas Klopstock; Marcus Deschauer; Volker Straub; Wolfgang Müller-Felber; Benedikt Schoser
Journal:  Neurology       Date:  2016-05-11       Impact factor: 9.910

4.  Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.

Authors:  Thomas Hundsberger; Marianne Rohrbach; Lukas Kern; Kai M Rösler
Journal:  J Neurol       Date:  2013-06-08       Impact factor: 4.849

5.  Reference intervals of α-glycosidase, β-glycosidase, and α-galactosidase in dried blood spot in a Turkish newborn population.

Authors:  Ozan Aldemir; Pelin Ergun; Sezgin Güneş; Ozge Altun Köroğlu; Mehmet Yalaz; Nilgün Kültürsay; Mahmut Coker; Eser Y Sözmen
Journal:  Eur J Pediatr       Date:  2013-05-10       Impact factor: 3.183

6.  Public support for neonatal screening for Pompe disease, a broad-phenotype condition.

Authors:  Stephanie Shifra Weinreich; Tessel Rigter; Carla Geertruida van El; Wybo Jan Dondorp; Pieter Johannes Kostense; Ans T van der Ploeg; Arnold J J Reuser; Martina Cornelia Cornel; Marloes Louise Catharina Hagemans
Journal:  Orphanet J Rare Dis       Date:  2012-03-14       Impact factor: 4.123

7.  At-Risk Testing for Pompe Disease Using Dried Blood Spots: Lessons Learned for Newborn Screening.

Authors:  Zoltan Lukacs; Petra Oliva; Paulina Nieves Cobos; Jacob Scott; Thomas P Mechtler; David C Kasper
Journal:  Int J Neonatal Screen       Date:  2020-12-21

8.  Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease.

Authors:  Nadia Sayeed; Pooja Sharma; Manahil Abdelhalim; Rahul Mukherjee
Journal:  Respirol Case Rep       Date:  2015-11-19

9.  Evaluation prevalence of Pompe disease in Iranian patients with myopathies of unknown etiology.

Authors:  Khadijeh Haji Naghi Tehrani; Elmira Sakhaeyan; Elnaz Sakhaeyan
Journal:  Electron Physician       Date:  2017-07-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.